WAVE LIFE SCIENCES LTD. Expense Breakdown
No Expense Breakdown for WVE on this site yet.
- 2026-06-30: Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM $37.32M; INHBE program $6.87M; DMD Programs $3.95M; AATD Program $2.99M.
- 2025-06-30: Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM $34.64M; INHBE program $3.52M; DMD Programs $2.68M; AATD Program $1.85M.
Source checked: the stored Expense Breakdown page for WVE.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM | INHBE program | DMD Programs | AATD Program | HD Programs |
|---|---|---|---|---|---|
| 2026-06-30 | $37.32M | $6.87M | $3.95M | $2.99M | $157.00K |
| 2025-06-30 | $34.64M | $3.52M | $2.68M | $1.85M | $789.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |